Bain said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry.

The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a ...

U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), ...

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), ...

Bain Capital entered a deal to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) from Mitsubishi Chemical Group for 510 ...

Bain Capital has agreed to acquire Tanabe Pharma, the pharma arm of Mitsubishi Chemical Group Corporation. The deal puts Tanabe Pharma at a valuation of about $3.3 billion. Founded in 1678, Tanabe ...

Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ("Tanabe Pharma", "MTPC" or "the Company") ...

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t ...

Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking ...

Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...